Enlivex Therapeutics to Present at The 2019 Jefferies Global Healthcare Conference
May 30 2019 - 8:35AM
Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage
immunotherapy company, today announced that company management will
make a corporate presentation at the Jefferies Global Healthcare
2019 conference being held in New York City. The presentation is
scheduled for June 7th 2019 at 1:00pm Eastern Time.
ALLOCETRA™ by Enlivex is a novel immunotherapy based on a unique
mechanism of action that targets life threatening diseases
that are defined as “unmet medical needs” such as preventing
or treating complications associated with bone marrow transplants
(“BMT”) and/or hematopoietic stem cell transplants (“HSCT); organ
dysfunction and acute multiple organ failure associated with sepsis
and enablement of an effective treatment of solid tumors via immune
checkpoint rebalancing.
For more information about the Jefferies Global Healthcare 2019
conference, visit
http://www.jefferies.com/IdeasAndPerspectives/Conferences/325/060419
ABOUT ENLIVEXEnlivex is a clinical stage
immunotherapy company, developing an allogeneic drug pipeline for
immune system rebalancing. Immune system rebalancing is critical
for the treatment of life-threatening immune and inflammatory
conditions which involve an out of control immune system (e.g.
Cytokine Release Syndrome) and for which there are no approved
treatments (unmet medical needs), as well as solid tumors
immune-checkpoint rebalancing. For more information,
visitwww.enlivex.com.
ENLIVEX CONTACT:
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivex-pharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jul 2023 to Jul 2024